Published in Women's Health Weekly, May 8th, 2003
Recent studies have suggested that oral estrogen replacement therapy and combined hormone replacement therapy resulted in an increase in C-reactive protein (CRP). CRP is a marker for inflammation in the blood vessels and is the strongest independent predictor of adverse cardiovascular events in otherwise healthy postmenopausal women.
In findings reported in the Journal of the American College of Cardiology, researchers at UT...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly